Medspa & Dermatology Biologics Supplier in Detroit, MI

How a medical director evaluates a new vendor

Medspas operating under physician supervision typically have the supervising or medical director review a new vendor's documentation before the practice adopts a product line. We provide the certificate of analysis, donor eligibility summary, and lot release record up front so that review can happen before the first order rather than after.

Dermatology and plastic surgery practices in Detroit that already maintain a vendor file for other injectable or biologic products generally fold our documentation into that same process.

Opening an NPI-verified account

Every account requires a verified NPI number, and ordering is limited to licensed physicians or to medspas ordering under physician supervision. Where a medspa has a named medical director, we recommend tying the account to that director's NPI so supervision and purchase history line up on the same record.

Verified accounts can schedule a peer-to-peer call to go through documentation and lot structure. These calls cover sourcing and paperwork only, not clinical protocol.

Cold-chain delivery to a Detroit practice

Cryopreserved formats ship overnight on dry ice in validated containers and must go into -80 degree Celsius storage on arrival; practices with multiple treatment rooms should plan intake so each lot is logged and stored before use. Lyophilized exosome and Wharton's jelly formats are shelf-stable and ship without that cold-chain requirement.

Lot-level identifiers let a practice trace any single unit back to its source lot, which is useful if a medical director later needs to confirm which lot was used on a given date.

Verify claims and classification with your own counsel

We make no disease, condition, or outcome claims about any product and recommend Detroit practices hold their own marketing and intake materials to the same standard. Exosome products carry no FDA approval and are generally regulated as biologic drugs; Wharton's jelly products are offered under the supplier's HCT/P framework, but whether a specific intended use meets the minimal-manipulation and homologous-use criteria is a question for the practice and its counsel.

We recommend confirming your supervision structure and marketing language with the Michigan medical board and your own healthcare attorney, especially in light of FDA warning letters issued to distributors in 2026 over website and social media claims in this category.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.